A clinical-stage pharmaceutical company focused on discovering, developing, and manufacturing next-generation protein therapeutics. The company develops protein therapies, including antibody-drug conjugates, using its cell-free protein synthesis technology, XpressCF, for the treatment of cancer and autoimmune diseases. Targeted cancers include multiple myeloma, non-Hodgkin's lymphoma, ovarian cancer, and endometrial cancer. Delaware-based.